Top

Archives of Gynecology and Obstetrics

Published in:

01-04-2012 | Gynecologic Oncology

The preoperative diagnosis of borderline ovarian tumors: a review of current literature

Authors: Matteo Morotti, Mario Valenzano Menada, David John Gillott, Pier Luigi Venturini, Simone Ferrero

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Abstract

Purpose

To evaluate the available information on the preoperative diagnosis of borderline ovarian tumors (BOTs).

Methods

Articles were identified through electronic databases (Medline and EMBASE, MEDLINE, PubMed), no date or language restrictions were placed; relevant citations were hand searched.

Results

Women with BOTs are more likely to have no symptom than women with invasive ovarian cancers; however, the type of symptoms is similar in patients with BOTs and invasive ovarian cancers. Up to 61% of women with BOTs have elevated CA-125; CA 19.9 and endoglin are not useful for diagnosing BOTs. Further studies are required to determine whether the measurements of calprotectin, oviductal glycoprotein 1 and growth differentiation factor-15 are useful for diagnosing BOTs. Ultrasonography and magnetic resonance imaging (MRI) are the mainstay for the diagnosis of BOTs. Combining MRI and positron emission tomography may facilitate the identification of BOTs.

Conclusion

After completion of this article, the reader should be aware of the symptoms of BOTs, the potential role and pitfalls of tumor marker measurement. In addition, the reader will understand the appearance of BOTs at imaging techniques; the reader will be able to compare and combine ultrasonography, MRI and positron emission tomography in diagnosing BOTs. In clinical practice, the reader should be better able to assess whether an ovarian mass is a benign tumor, a BOT or an invasive cancer.

Chu CS, Rubin SC (2006) Epidemiology, staging and clinical characteristics. In: Bristow RE, Karlan BY (eds) Surgery for ovarian cancer: principles and practice, 1st edn. Taylor & Francis, Abington, pp 1–37

Swanton A, Bankhead CR, Kehoe S (2007) Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol 135:3–7PubMedCrossRef

Wong HF, Low JJ, Chua Y et al (2007) Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer 17:342–349PubMedCrossRef

Goff BA, Mandel LS, Melancon CH et al (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705–2712PubMedCrossRef

Hamilton W, Peters TJ, Bankhead C et al (2009) Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 339:b2998PubMedCrossRef

Ranney B, Ahmad MI (1979) Early identification, differentiation and treatment of ovarian neoplasia. Int J Gynaecol Obstet 17:209–218PubMed

Eltabbakh GH, Yadav PR, Morgan A (1999) Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 75:476–479PubMedCrossRef

Vine MF, Ness RB, Calingaert B et al (2001) Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 83:466–471PubMedCrossRef

Webb PM, Purdie DM, Grover S et al (2004) Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 92:232–239PubMedCrossRef

10.

Olsen CM, Cnossen J, Green AC et al (2007) Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 28:376–380PubMed

11.

Paulsen T, Kaern J, Kjaerheim K et al (2005) Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 88:31–37PubMedCrossRef

12.

Rice LW, Lage JM, Berkowitz RS et al (1992) Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 46:226–229PubMedCrossRef

13.

Zanetta G, Vergani P, Lissoni A (1994) Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 73:637–641PubMedCrossRef

14.

Darai E, Teboul J, Walker F et al (1996) Epithelial ovarian carcinoma of low malignant potential. Eur J Obstet Gynecol Reprod Biol 66:141–145PubMedCrossRef

15.

Tamakoshi K, Kikkawa F, Shibata K et al (1996) Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 62:67–72PubMedCrossRef

16.

Engelen MJ, de Bruijn HW, Hollema H et al (2000) Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 78:16–20PubMedCrossRef

17.

Gotlieb WH, Soriano D, Achiron R et al (2000) CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 183:541–546PubMedCrossRef

18.

Takemori M, Nishimura R, Hasegawa K (2002) Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors. Acta Obstet Gynecol Scand 81:157–161PubMedCrossRef

19.

Ayhan A, Guven S, Guven ES et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484–490PubMedCrossRef

20.

Kumpulainen S, Kuoppala T, Leminen A et al (2007) Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstet Gynecol Scand 86:610–614PubMedCrossRef

21.

Kolwijck E, Thomas CM, Bulten J et al (2009) Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer 19:1335–1338PubMedCrossRef

22.

Lenhard MS, Nehring S, Nagel D et al (2009) Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med 47:537–542PubMedCrossRef

23.

Van Calster B, Timmerman D, Bourne T et al (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 99:1706–1714PubMedCrossRef

24.

Tempfer CB, Polterauer S, Bentz EK et al (2007) Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 107:248–252PubMedCrossRef

25.

Kelly PJ, Archbold P, Price JH et al (2010) Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 63:169–173PubMedCrossRef

26.

Hata K, Hata T, Manabe A et al (1992) Ovarian tumors of low malignant potential: transvaginal Doppler ultrasound features. Gynecol Oncol 45:259–264PubMedCrossRef

27.

Ehrchen JM, Sunderkötter C, Foell D et al (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557–566PubMedCrossRef

28.

Ferrero S, Gillott DJ, Remorgida V et al (2007) Proteomic analysis of peritoneal fluid in women with endometriosis. J Proteome Res 6:3402–3411PubMedCrossRef

29.

Ødegaard E, Davidson B, Elgaaen BV et al (2008) Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 198:418.e1–7PubMedCrossRef

30.

Ødegaard E, Davidson B, Engh V et al (2008) Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 199:533.e1–8PubMedCrossRef

31.

Maines-Bandiera S, Woo MM, Borugian M et al (2010) Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer 20:16–22PubMedCrossRef

32.

Staff AC, Bock AJ, Becker C et al (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118:237–243PubMedCrossRef

33.

Begum FD, Høgdall E, Kjaer SK et al (2009) Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol 113:221–227PubMedCrossRef

34.

Pascual MA, Tresserra F, Grases PJ et al (2002) Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound 30:76–82PubMedCrossRef

35.

Exacoustos C, Romanini ME, Rinaldo D et al (2005) Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 25:50–59PubMedCrossRef

36.

Fruscella E, Testa AC, Ferrandina G et al (2005) Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol 26:644–650PubMedCrossRef

37.

Yazbek J, Raju KS, Ben-Nagi J et al (2007) Accuracy of ultrasound subjective ‘pattern recognition’ for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 29:489–495PubMedCrossRef

38.

Alcázar JL, Errasti T, Mínguez JA et al (2001) Sonographic features of ovarian cystadenofibromas: spectrum of findings. J Ultrasound Med 20:915–919PubMed

39.

Emoto M, Udo T, Obama H et al (1998) The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. Gynecol Oncol 70:351–357PubMedCrossRef

40.

Wu CC, Lee CN, Chen TM et al (1994) Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer 73:1251–1256PubMedCrossRef

41.

Tepper R, Lerner-Geva L, Altaras MM et al (1995) Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med 14:731–734PubMed

42.

Reles A, Wein U, Lichtenegger W (1997) Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 25:217–225PubMedCrossRef

43.

Tekay A, Jouppila P (1992) Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color Doppler ultrasound. Ultrasound Obstet Gynecol 2:338–344PubMedCrossRef

44.

Zanetta G, Lissoni A, Cha S et al (1995) Pre-operative morphological and colour Doppler features of borderline ovarian tumours. Br J Obstet Gynaecol 102:990–996PubMedCrossRef

45.

Yazbek J, Ameye L, Timmerman D et al (2010) Use of ultrasound pattern recognition by expert operators to identify borderline ovarian tumors: a study of diagnostic performance and interobserver agreement. Ultrasound Obstet Gynecol 35:84–88PubMedCrossRef

46.

Ordén MR, Jurvelin JS, Kirkinen PP (2003) Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 226:405–410PubMedCrossRef

47.

Marret H, Sauget S, Giraudeau B et al (2004) Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med 23:1629–1639PubMed

48.

Testa AC, Timmerman D, Van Belle V et al (2009) Intravenous contrast ultrasound examination using contrast-tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components. Ultrasound Obstet Gynecol 34:699–710PubMedCrossRef

49.

Lalwani N, Shanbhogue AK, Vikram R et al (2010) Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 194:330–336PubMedCrossRef

50.

Bent CL, Sahdev A, Rockall AG et al (2009) MRI appearances of borderline ovarian tumours. Clin Radiol 64:430–438PubMedCrossRef

51.

deSouza NM, O’Neill R, McIndoe GA et al (2005) Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR Am J Roentgenol 184:999–1003PubMed

52.

Bazot M, Daraï E, Nassar-Slaba J et al (2008) Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr 32:712–723PubMedCrossRef

53.

Van Vierzen PB, Massuger LF, Ruys SH et al (1998) Borderline ovarian malignancy: ultrasound and fast dynamic MR findings. Eur J Radiol 28:136–142PubMedCrossRef

54.

Imaoka I, Wada A, Kaji Y et al (2006) Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics 26:1431–1448PubMedCrossRef

55.

Thomassin-Naggara I, Bazot M, Daraï E et al (2008) Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 248:148–159PubMedCrossRef

56.

Thomassin-Naggara I, Cuenod CA, Darai E et al (2008) Dynamic contrast-enhanced MR imaging of ovarian neoplasms: current status and future perspectives. Magn Reson Imaging Clin N Am 16:661–672PubMedCrossRef

57.

Bazot M, Nassar-Slaba J, Thomassin-Naggara I et al (2006) MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology. Eur Radiol 16:2687–2699PubMedCrossRef

58.

Spencer JA, Ghattamaneni S (2010) MR imaging of the sonographically indeterminate adnexal mass. Radiology 256:677–694PubMedCrossRef

59.

Fujii S, Kakite S, Nishihara K et al (2008) Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging 28:1149–1156PubMedCrossRef

60.

Thomassin-Naggara I, Daraï E, Cuenod CA et al (2009) Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol 19:1544–1552PubMedCrossRef

61.

Takeuchi M, Matsuzaki K, Nishitani H (2010) Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr 34:173–176PubMedCrossRef

62.

Medeiros LR, Freitas LB, Rosa DD et al (2011) Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol 204:67.e1–10PubMedCrossRef

63.

Buy JN, Ghossain MA, Sciot C et al (1991) Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 178:811–818PubMed

64.

Lapela M, Leskinen-Kallio S, Varpula M et al (1995) Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 36:2196–2200PubMed

65.

Grab D, Flock F, Stöhr I et al (2000) Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77:454–459PubMedCrossRef

66.

Rieber A, Nüssle K, Stöhr I et al (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 177:123–129PubMed

67.

Ju W, Kim SC (2007) Discrepancy between magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography imaging in a case of borderline ovarian tumor. Int J Gynecol Cancer 17:1031–1033PubMedCrossRef

68.

Yamamoto Y, Oguri H, Yamada R et al (2008) Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 102:124–127PubMedCrossRef

69.

Jung DC, Choi HJ, Ju W et al (2008) Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer 18:637–641PubMedCrossRef

70.

Risum S, Høgdall C, Loft A et al (2007) The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 105:145–149PubMedCrossRef

71.

Nam EJ, Yun MJ, Oh YT et al (2010) Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 116:389–394PubMedCrossRef

72.

Poncelet C, Fauvet R, Yazbeck C et al (2010) Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study. Eur J Surg Oncol 36:1066–1072PubMedCrossRef

73.

74.

Van Holsbeke C, Van Calster B, Valentin L et al (2007) External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group. Clin Cancer Res 13:4440–4447PubMedCrossRef

75.

Jacobs I, Oram D, Fairbanks J et al (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 97:922–929CrossRef

76.

Outwater EK, Huang AB, Dunton CJ et al (1997) Papillary projections in ovarian neoplasms: appearance on MRI. J Magn Reson Imaging 7:689–695PubMedCrossRef

Title: The preoperative diagnosis of borderline ovarian tumors: a review of current literature
Authors: Matteo Morotti
Mario Valenzano Menada
David John Gillott
Pier Luigi Venturini
Simone Ferrero
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-011-2194-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The preoperative diagnosis of borderline ovarian tumors: a review of current literature

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Selective and non-selective intrauterine growth restriction in twin pregnancies: high-risk factors and perinatal outcome

Giant cell tumour of the ovary in a 70-year-old nulliparous woman: a case report and review of literature

Placental alpha microglobulin-1 (AmniSure® test) for detection of premature rupture of fetal membranes

Bone mineral density is not associated with homocysteine level, folate and vitamin B12 status

Obesity and perioperative outcomes in endometrial cancer surgery

Retrospective analysis of the efficacy of perioperative use of the cell salvage and autologous blood recovery system during laparoscopic myomectomy